Thus, MAPK mutational status or ERK activities can modulate ErbB3 activation level in HNSCC, suggesting the need for precautions when using ErbB3 inhibitors in MAPK-mutant HNSCC patients. The gene discussed is MAPK1; the disease is head and neck squamous cell carcinoma.